THERAPY DOSSIER · th-d7cc595489e0

Laminin-mimetic bioactive peptide amphiphile nanofibre system (LM/E-PA)

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28690008 ↗2017Reported benefit

Laminin mimetic peptide nanofibers regenerate acute muscle defect.

RatOtherSprague-DawleyMaleLocal injection into the injured tibialis anterior muscleAdministered at the time of acute muscle injury

Model: Acute skeletal muscle defect created in the tibialis anterior muscle

Laminin-mimetic peptide nanofibres significantly promoted satellite cell activation and accelerated myofibrillar regeneration after acute muscle injury in rats. Treatment reduced the time required for structural and functional repair of the skeletal muscle without additional cell or growth factor t…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…